期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地精丹方剂加减及免疫调节剂治疗蕈样肉芽肿疗效观察 被引量：2

下载PDF
导出
作者 陈明华 肖丽明 张晓彬 陈连军 陈健民
机构地区 复旦大学上海医学院皮肤性病学系 复旦大学附属华山医院中西医结合科 河南信阳卫校附属医院皮肤科
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2005年第12期850-851,共2页 Journal of Clinical Dermatology
基金 上海市科学技术发展基金资助项目(024119089)
关键词 蕈样肉芽肿 中药 免疫调节剂
分类号 R730.263 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome:clinical prognostic factors and risk for disease progression [J].Arch Dermatol, 2003, 139(7): 857-866.
  • 2陈明华,邱丙森.小剂量α-干扰素-2b治疗皮肤T细胞淋巴瘤　[J].中华皮肤科杂志,1995,28(5):324-325. 被引量：2
  • 3Papa G, Tura S, Mandelli F, et al. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?[J]. Br J Haematol, 1991, 79 Suppl 1: 48-51.
  • 4陈明华,陈连军,邱丙森.光化学疗法联合干扰素治疗蕈样肉芽肿30例[J].临床皮肤科杂志,2002,31(12):767-769. 被引量：3
  • 5Bunn PA Jr, Ihde DC, Foon KA. Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell Lymphomas[J].Int J Cancer Suppl, 1987, 1: 9-13.

二级参考文献11

  • 1[8]McGregor JM, Crook T, Fraser-Andrews EA, et al. Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas[J]. J Invest Dermatol, 1999, 112(3): 317-321.
  • 2[9]Bunn PA Jr, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome) [J]. Ann Intern Med, 1994,121(8):592-602.
  • 3[10]Jumbou O, NGuyen JM, Tessier MH, et al. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa[J]. Br J Dermatol, 1999,140(3):427-431.
  • 4[11]Rupoli S, Barulli S, Guiducci B, et al. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous T-cell Lymphoma Multicenter Study Group [J]. Haematological,1999,84 (9):809-813.
  • 5[1]Herrmann JJ, Roenigk HH Jr, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up [J]. J Am Acad Dermatol ,1995,33(2Pt1):234-242.
  • 6[2]Zackheim HS, Epstein EH Jr, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143patients[J]. J Am Acad Dermatol, 1990,22(5 Pt1): 802-810.
  • 7[3]Reddy S, Parker CM, Shidnia H, et al. Total skin electron beam radiation therapy for mycosis fungoides[J]. Am J Clin Oncol,1992,15(2):119-124.
  • 8[4]Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon-2α plus acitretin versus interferon-2α plus PUVA in patients with cutaneous T-cell lymphoma stages Ⅰ andⅡ [J]. Blood, 1998, 92(10): 3578-3581.
  • 9[5]Bunn PA Jr, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas[J]. Cancer Treat Rep,1979,63(4):725-728.
  • 10[6]Kim YH, Jensen RA, Watanable GL, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis[J]. Arch Dermatol, 1996, 132(11): 1309-1313.

共引文献3

同被引文献21

  • 1Jumbou O, N’Guyen JM, Tessier MH, et al. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa[J]. Br J Dermatol, 1999, 140(3): 427-431.
  • 2Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)[J]. Blood, 2007, 110(6): 1713-1722.
  • 3Wolff JM, Zitelli JA, Rabin BS, et al. Intralesional interferon in the treatment of early mycosis fungoides[J]. J Am Acad Dermatol, 1985, 13(4): 604-612.
  • 4Vonderheid EC, Thompson R, Smiles KA, et al. Recombinant interferon alfa-2b in plaque-phase mycosis fungoides. Intralesional and low-dose intramuscular therapy[J]. Arch Dermatol, 1987, 123(6): 757-763.
  • 5Dréno B, Claudy A, Meynadier J, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate[J]. Br J Dermatol, 1991, 125(5): 456-459.
  • 6Hugh Z, Thestrup-Pedersen K. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma[J]. J Invest Dermatol, 1990, 95(Suppl 6): 206S-208S.
  • 7Shimauchi T, Sugita K, Nishio D, et al. Alterations of serum Th1 and Th2 chemokines by combination therapy of interferon-gamma and narrowband UVB in patients with mycosis fungoides[J]. J Dermatol Sci, 2008, 50(3): 217-225.
  • 8Bunn PA, Foon KA, Inde DC, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas[J]. Ann Intern Med, 1984, 101(4): 484-487.
  • 9Kohn EC, Steis RG, Sausville EA, et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome[J]. J Clin Oncol, 1990, 8(1): 155-160.
  • 10Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma[J]. J Am Acad Dermatol, 1989, 20(3): 395-407.

引证文献2

临床皮肤科杂志
2005年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部